SO2020288_bcamonitor_WEB-updates_webinarWitjes

Oct 2, 2020 | Webinar

Interested in the place of urinary markers in NMIBC follow-up?

Watch a webinar by Prof. Fred Witjes

On Thursday 24 September 2020, Nucleix, Israel and Oncotest-Rhenium, Israel organised the webinar “Follow-up of NMIBC, Including the Place of Urinary Markers”. The webinar included 45 minutes lecture by Prof. Dr. Fred Witjes, Professor of oncological urology at Radboud UMC Nijmegen, the Netherlands and 15 minutes Q&A, and was chaired by Dr. Dov Engelstein, Chairman of the Israel Association of Urology (IAU), and Dr. Ran Katz, Associate in the Israel Association of Urology (IAU).

Watch this webinar to learn more about:

The current guidelines on treatment and follow-up of Non Muscle-Invasive Bladder Cancer (NMIBC)
The pitfalls of the current follow-up procedures
Urinary markers in follow-up and promising results from clinical studies
The benefits of urinary markers in general and during the COVID-19 pandemic

Moreover, Prof. Dr. Fred Witjes provided insights on how he implements the Bladder EpiCheck® urine test in his clinical practice.

Download the free slide resource and brochure

Share this on your favourite network:

All updates

Other updates

The diagnostic value of urinary biomarkers in UTUC

Feb 2, 2024 | Publication

Reviewed by Mr. Hugh Mostafid (Royal Surrey County Hospital, Guildford, UK) UTUC: similarities and differences compared to bladder cancer While bladder tumours account for 90-95% of all urothelial carcinomas (UCa), only 5-10% of UCa cases involve the upper urinary...

Including Bladder EpiCheck® in NMIBC surveillance leads to a major reduction in healthcare costs

Jan 19, 2024 | Publication

Urinary biomarker tests, including Bladder EpiCheck®, are reimbursed from January 2024 in the Netherlands Reviewed by Prof. Joost Boormans (Erasmus MC Cancer Institute, Rotterdam, The Netherlands) Pitfalls of the current standard for NMIBC follow-up Due to the high...

Henry with intermediate-risk NMIBC finds follow-up cystoscopies burdensome. What now?

Jun 30, 2023 | Clinical case

Henry, 70 years old, used to work as a creative director in a chocolate factory. Once, he designed chocolates that looked like broccoli. Too bad, they were not favoured by the clients … He was initially diagnosed with a solitary small Ta low-grade (LG) tumour. He...

Privacy policy

Disclaimers

✉ info@bcamonitor.org